TL;DR
This study reveals how a 10-day complete fast dramatically reshapes the gut microbiome and serum metabolome in healthy men, shifting energy metabolism towards fat utilization and establishing a new homeostatic state. A key finding is the significant increase of Ruthenibacterium lactatiformans, a gut bacterium that shows promise in mitigating obesity and metabolic disorders.
What Problem Does This Paper Address?
While fasting has a long history and is increasingly recognized for its health benefits, the precise mechanisms by which it impacts our bodies, particularly concerning the gut microbiome and metabolic processes, remain unclear. Intermittent fasting is well-studied, but the effects of prolonged complete fasting (CF) are less understood. This paper aims to bridge that gap by investigating the temporal changes in the gut microbiome and serum metabolome during a 10-day CF in healthy adult males, and crucially, how these two systems interact to influence metabolic health. Understanding these interactions is vital for developing evidence-based fasting strategies for therapeutic purposes.
Methods
The researchers employed a multi-omics approach to track changes over time. Key techniques included:
- Metagenomic Sequencing: Used to analyze the composition and diversity of the gut microbiome from fecal samples. This involved DNA extraction, library preparation, and high-throughput sequencing, followed by bioinformatics analysis to identify bacterial taxa and their relative abundances.
- Untargeted Metabolomics (UHPLC-MS): Employed to identify and quantify a wide range of metabolites in serum samples. This technique allows for a broad overview of metabolic changes without pre-selecting specific compounds.
- Statistical Analysis: A suite of statistical methods was used, including alpha and beta diversity analysis, principal coordinate analysis (PCoA), PERMANOVA, time-series analysis (STEM), Spearman correlation, and multivariate analysis (OPLS-DA, PCA) to identify significant changes, associations, and patterns.
- Animal Experiments: To validate findings related to specific bacteria and metabolites, in vivo studies were conducted using mice fed a high-fat diet (HFD) and treated with Ruthenibacterium lactatiformans or indolelactic acid (ILA).
Datasets
The study utilized data collected from 13 healthy male adult volunteers over several time points:
- Baseline Period (BF): Before fasting.
- Complete Fasting (CF): Samples collected on days 3 (CF3) and 9 (CF9).
- Calorie Restriction (CR): Samples collected on day 3 (CR3) of a transition diet.
- Full Recovery (FR): Samples collected on day 5 (FR5) of returning to a regular diet.
Fecal and serum samples were collected at these time points.
Key Insights and Ideas
- Gut Microbiome Reconfiguration: The 10-day fast significantly altered the gut microbiome's diversity and composition. Notably, there was a dramatic increase in Proteobacteria and a decrease in Bacteroidetes and Firmicutes. This suggests a profound shift in the microbial ecosystem's structure.
- Ruthenibacterium lactatiformans Emerges: This specific bacterium saw a significant increase during fasting and showed strong correlations with fat metabolism indicators. Its potential as a probiotic for metabolic health is a major highlight.
- Metabolic Shift to Fat Utilization: Serum metabolomics revealed changes pointing towards a switch from glucose to fatty acid metabolism, including increased beta-oxidation of very long-chain fatty acids and enhanced carnitine synthesis pathways.
- Interplay is Key: The study strongly emphasizes the intricate relationship between gut bacteria and serum metabolites. Specific bacteria, like R. lactatiformans, were directly linked to changes in metabolites involved in lipid and tryptophan metabolism.
- Tryptophan Metabolism Altered: While overall tryptophan levels decreased, the metabolite indolelactic acid (ILA) increased significantly and was strongly correlated with R. lactatiformans. This suggests a bacterial influence on tryptophan breakdown pathways.
- Animal Model Validation: The in vivo experiments confirmed that R. lactatiformans and ILA could mitigate HFD-induced obesity, glucose intolerance, and dyslipidemia, lending strong support to their therapeutic potential.
Key Results
- Microbiome Changes: Proteobacteria increased by ~6-fold, while Bacteroidetes and Firmicutes decreased by ~50% and ~34%, respectively.
- Metabolite Shifts: Fatty acylcarnitines and tryptophan derivatives were significantly altered and correlated with gut bacteria.
- Bacterial Correlation: Ruthenibacterium lactatiformans showed strong positive correlations with several fatty acylcarnitines.
- Animal Study Outcomes: Administration of R. lactatiformans or ILA in mice fed an HFD led to reduced body weight gain, improved lipid profiles, and better glucose tolerance compared to the HFD-only group.
Limitations and Future Work
The authors acknowledge that this was a pilot study with a small sample size (13 male volunteers), which limits the generalizability of the findings. They also note that the specific functions of all altered gut bacteria require further exploration.
Future work should focus on:
- Larger-scale studies to confirm these findings in diverse populations.
- Further investigation into the precise mechanisms by which Ruthenibacterium lactatiformans and ILA exert their beneficial effects.
- Exploring the role of nitrogen fixation by certain gut bacteria during fasting.
- Developing R. lactatiformans as a probiotic for treating metabolic diseases.
Summary updated